Keytruda alone generated $25 billion last year across multiple indications. That still left room for rivals to generate ...

However, BMS’ setback is further good news for MSD’s Keytruda, which now looks increasingly likely to become the dominant player in NSCLC globally, after Opdivo failed to show efficacy as a ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BMS' drug ...

section above. Like Keytruda, Opdivo is a programmed death receptor-1 (PD-1) blocking antibody (type of immune system protein). These drugs help your immune system detect cancer cells in your body ...

Tumor cells exploit this checkpoint to evade immune attacks before they begin. Keytruda, Opdivo, and Tencentriq are all ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Aethlon Medical (AEMD) announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the ...

JMP notes despite the incredible clinical and commercial success of Merck & Co. Inc’s (NYSE:MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first ...